Financials data is unavailable for this security.
View more
Year on year Jiangsu Lianhuan Pharmaceutical Co Ltd had net income fall -4.50% from 141.37m to 135.01m despite a 11.20% increase in revenues from 1.96bn to 2.17bn. An increase in the cost of goods sold as a percentage of sales from 46.68% to 51.98% was a component in the falling net income despite rising revenues.
| Gross margin | 48.56% |
|---|---|
| Net profit margin | 6.66% |
| Operating margin | 7.87% |
| Return on assets | 5.50% |
|---|---|
| Return on equity | 10.26% |
| Return on investment | 11.40% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Jiangsu Lianhuan Pharmaceutical Co Ltd fell by 58.86m. However, the company earned 160.70m from its operations for a Cash Flow Margin of 7.39%. In addition the company used 184.69m on investing activities and also paid 35.10m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 4.81 |
|---|---|
| Tangible book value per share | 4.00 |
More ▼
Balance sheet in CNYView more
| Current ratio | 0.9852 |
|---|---|
| Quick ratio | 0.7093 |
| Total debt/total equity | 0.6106 |
|---|---|
| Total debt/total capital | 0.3522 |
More ▼
Growth rates in CNY
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -4.50%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 1.27% |
|---|---|
| Div growth rate (5 year) | 13.97% |
| Payout ratio (TTM) | 31.40% |
| EPS growth(5 years) | 12.91 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -0.3775 |
More ▼
